Peking University Cancer Hospital - Academic Profile

Publications

View All

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

2021 The Lancet 2580 citations

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Xinyi Guo , Yuanyuan Zhang , Liangtao Zheng +16 more

2018 Nature Medicine 1675 citations

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

Ih‐Chang Hsu , Robert A. Metcalf , Tai‐ping Sun +3 more

1991 Nature 1530 citations

Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries

Hongmei Zeng , Wanqing Chen , Rongshou Zheng +41 more

From 2003 to 2005, standardised 5-year cancer survival in China was much lower than in developed countries and varied substantially by geographical area. Monitoring population-l...

2018 The Lancet Global Health 1487 citations

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim , Vera Hirsh , Tony Mok +15 more

2008 The Lancet 1240 citations

Institution Info

Type: healthcare
Country: CN
Publications: 5
Citations: 8,512

External Links

Identifiers

ROR: https://ror.org/00nyxxr91